October 26, 2026

#362: Paul Coletta, Co-Founder and CEO of Vero Bioscience

Listen On:
Image of Paul Coletta, with text
Presented by
EGYM logo

Today, I’m joined by Paul Coletta, co-founder & CEO of Vero Bioscience.

A predictive health company, Vero uses proteomic blood tests and proprietary AI to measure and improve organ-level aging.

In this episode, we discuss building a closed-loop health system powered by proteomics.

We also cover:

  • Why organ-level data beats whole-body scores
  • How proteomics differs from other biological age measures
  • Reproducibility, clinical validation, and roadmap to launch

The Fitt Insider Podcast is brought to you by EGYM. Visit EGYM.com to learn more about its smart fitness ecosystem for fitness and health facilities.


Chapters:
(00:00) Introduction
(01:30) Paul’s background
(02:45) 11K protein measurement
(04:00) Stanford technology
(05:00) Scientific validation
(06:00) Biological age vs. organ age
(07:30) Actionability and reproducibility
(10:00) Clinical validation approach
(12:15) Closed-loop compass system
(14:00) Organ-specific interventions
(15:30) Healthspan vs. immortality
(19:15) Clinical partnerships strategy
(22:00) Competitive differentiation
(25:00) Direct-to-consumer roadmap
(27:30) Regulatory and cost challenges
(28:30) Educating the market
(30:00) Balancing rigor and marketing
(34:00) Patient-led future
(36:45) Where to follow; closing remarks

Strategic intelligence for the future of health.

We break down how fitness, wellness, and healthcare are converging — and what it means for business, culture, and capital.

No thanks.